Arcus Biosciences (NYSE:RCUS) Stock Gets Price Target Boost from Truist Financial

21 Oct 2026, 14:01 by Danessa Lincoln · The Markets Daily

Arcus Biosciences (NYSE:RCUS – Get Free Report) had its target price boosted by investment analysts at Truist Financial from $40.00 to $41.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price target suggests a potential upside of 73.08% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. TD Cowen assumed coverage on shares of Arcus Biosciences in a research report on Wednesday, September 16th. They issued a “buy” rating on the stock. Wedbush lifted their target price on shares of Arcus Biosciences from $43.00 to $49.00 and gave the stock an “outperform” rating in a report on Wednesday. Wall Street Zen upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. HC Wainwright upped their price target on shares of Arcus Biosciences from $32.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Thursday, October 15th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.18.

Get Our Latest Analysis on Arcus Biosciences

Arcus Biosciences Stock Up 7.0%

RCUS opened at $23.69 on Wednesday. The stock’s fifty day simple moving average is $26.73 and its 200 day simple moving average is $26.25. Arcus Biosciences has a 1-year low of $16.41 and a 1-year high of $31.74. The stock has a market cap of $3.02 billion, a PE ratio of -6.07 and a beta of 0.94. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The firm had revenue of $41.00 million during the quarter, compared to analysts’ expectations of $21.98 million. The firm’s revenue for the quarter was down 74.4% on a year-over-year basis. As a group, research analysts expect that Arcus Biosciences will post -3.55 earnings per share for the current year.

Insider Activity

In other news, CAO Alexander Azoy sold 2,827 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the sale, the chief accounting officer owned 39,581 shares of the company’s stock, valued at approximately $1,187,430. The trade was a 6.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Arcus Biosciences in the second quarter valued at approximately $506,113,000. Parkman Healthcare Partners LLC bought a new stake in shares of Arcus Biosciences in the second quarter valued at approximately $28,341,000. Bank of America Corp DE bought a new position in Arcus Biosciences during the 2nd quarter worth $25,759,000. Bank of New York Mellon Corp bought a new position in Arcus Biosciences during the 2nd quarter worth $16,741,000. Finally, Renaissance Technologies LLC raised its holdings in Arcus Biosciences by 1,198.8% in the 1st quarter. Renaissance Technologies LLC now owns 424,700 shares of the company’s stock valued at $9,174,000 after acquiring an additional 392,000 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

Positive Sentiment: Wedbush raised its price target to $49 from $43 and reiterated an “outperform” rating, implying substantial upside from the reference price. The upgrade reflects increased confidence in Arcus’s pipeline following the casdatifan data release. Benzinga analyst rating report
Positive Sentiment: ARC-20 results showed casdatifan activity across first-, second- and later-line clear cell renal cell carcinoma. Reported progression-free survival and response rates were described as superior or competitive with historical benchmarks, while safety appeared manageable. The breadth of activity supports the potential for casdatifan to become a foundational treatment across multiple lines of therapy. Arcus ARC-20 data report
Neutral Sentiment: Investor reaction to the data was mixed. Some analysts characterized the results as encouraging and the stock surged during the session, while another report noted an initial 6% decline as investors scrutinized the trial details. The mixed response highlights that additional clinical validation will be important. Seeking Alpha ARC-20 market reaction
Negative Sentiment: Valuation leaves RCUS vulnerable to clinical setbacks. The stock trades at high sales multiples, reflecting significant expectations for casdatifan and other pipeline assets. Arcus also faces potential pressure from an anticipated loss in the upcoming quarterly report, according to Zacks. Seeking Alpha valuation analysis

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.